Vivos Therapeutics Inc. is “One to Watch”

• Obstructive sleep apnea affects millions of people of all ages. It is estimated that OSA costs the US economy $165B annually. The Vivos technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated hundreds of millions of people globally who suffer from OSA.
• As dentists have hundreds of patients of all ages suffering from OSA, the Vivos System presents a multi-million dollar revenue opportunity for dental practices.
• Vivos is helping address challenges throughout the world, reducing the overall cost of health care by focusing on a prevalent condition which is linked to many of the most expensive health care problems.
• The Vivos System is thought to be the most significant breakthrough in OSA treatment since CPAP.
• The system’s treatment time is a fraction of that of its alternatives—patients can find lasting relief in a matter of months, eliminating the need for surgery or a lifetime of therapy.
• Vivos® Integrated Practices are supported by a network of clinical, practice and market advisors who provide guidance, collaboration, various capacities of coaching, and market intelligence in support of growth and distribution.

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. is an emerging global leader in the treatment of obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to eradicate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://nnw.fm/VVOS

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.